Transjugular intrahepatic portosystemic shunt (TIPS) creation using bare stents is a second-line treatment for complications of portal hypertension due in part to the relatively high number of reinterventions and the occurrence of new or worsened encephalopathy. Initially, custom-made stent-grafts were used for TIPS revision in cases of biliary fistulae. Subsequently, custom stent-grafts were used for de novo TIPS creation. With the introduction of the VIATORR 1 TIPS endoprosthesis a dedicated stent-graft became available for TIPS creation and revision. The VIATORR 1 demonstrated its efficacy and superiority to uncovered stents in retrospective analyses, case-matched analyses, and randomized studies. The improved patency of stent-grafts has led many to requestion the role of TIPS as a second-line therapy. Currently, randomized trials are warranted to redefine the role of TIPS in the treatment of complications of portal hypertension.KEYWORDS: Transjugular portosystemic shunt, stents, stent-grafts, complication, prognosisObjectives: Upon completion of this article, the reader should understand the indications and expected results for placing stent-grafts for the de novo creation and revision of TIPS. Accreditation: Tufts University School of Medicine (TUSM) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit: TUSM designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physicians Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.The creation of a portosystemic shunt is an effectivetreatmentfor complicationsofportalhypertension such as prevention of variceal bleeding or refractory ascites. The major problem with transjugular intrahepatic portosystemic shunts (TIPS) is their limited and unpredictable patency. In a small proportion of patients, the tract remains stenosis free, but the majority of TIPS develop sporadic or frequent shunt tract stenoses, thromboses, and/or outflow hepatic venous stenoses, causing clinical dysfunction with recurrence of portal hypertension. Depending on the definition of shunt patency used and the methods of follow-up and timing of surveillance, stenosis greater than 50% and recurrent portal hypertension develop in 25 to 50% of cases within 6 to 12 months after shunt creation.